|
Post by loparn on Apr 21, 2017 17:52:30 GMT
WntResearch's CSO Tommy Andersson's research group in Lund now after today's news has published results from a total of (at least) 16 different in vitro experiments which all show that Wnt-5a and the drug candidate Foxy-5 has similar beneficial effect on human cells and in two cases mouse cells. This is very promising since the Phase 1b study showed that Foxy-5 reaches and signals in cancer cells in patients with low or no Wnt-5a expression, and importantly it has been shown earlier that a high compared to low or no Wnt-5a expression is associated with around 2-8 years longer median survival in breast, colon and prostate cancers. So Foxy-5 should most likely do qualitatively something similar in future Phase II studies.
HB2 breast cells with eliminated Wnt-5a : anti migration effect of both Foxy-5 and Wnt-5a
4T1 mouse breast cancer cells : anti migration effect of both Foxy-5 and Wnt-5a
4T1 mouse breast cancer cells : anti invasion effect of both Foxy-5 and Wnt-5a
MDA-MB-231 breast cancer cells ER-positive : anti invasion effect of both Foxy-5 and Wnt-5a
MDA-MB-231 breast cancer cells ER-negative :anti invasion effect of both Foxy-5 and Wnt-5a
MDA-MB-231 breast cancer cells : anti migration effect of both Foxy-5 and Wnt-5a
MDA-MB-231 breast cancer cells + lactate : anti migration effect of both Foxy-5 and Wnt-5a
MDA-MB-468 breast cancer cells : antimigration effect of both Foxy-5 and Wnt-5a
MDA-MB-468 breast cancer cells + lactate : antimigration effect of both Foxy-5 and Wnt-5a
MD-MB-268 breast cancer cells : upregulation of 15-PGDH of both Foxy-5 and Wnt-5a
22Rv1 prostate cancer cells : anti invasion effect of both Foxy-5 and Wnt-5a
DU145 prostate cancer cells : anti invasion effect of both Foxy-5 and Wnt-5a
HT-29 colon cancer cells : uppregulation of 15-PGDH of both Foxy-5 and Wnt-5a
HT-29 colon cancer cells: downregulation of betacatenin of both Foxy-5 and Wnt-5a
Caco-2 colon cancer cells : upregulation of 15-PGDH of both Foxy-5 and Wnt-5a
Caco-2 colon cancer cells : downregulation of betacatenin of both Foxy-5 and Wnt-5a
|
|
|
Post by loparn on May 17, 2017 6:48:13 GMT
|
|
|
Post by loparn on Jul 18, 2017 8:18:47 GMT
No further news release has I arrived yet regarding the final results from Phase Ib study, the retrospective study or how the company will raise capital for the Phase II study - will there be a deal with Big Pharma or a regular stock emission ? As a shareholder one just have to wait and see...
|
|
|
Post by loparn on Aug 14, 2017 6:11:18 GMT
|
|
|
Post by loparn on Aug 17, 2017 9:29:39 GMT
The Q2-report is released today and surprisingly the company has taken a short term loan of SEK 10 million which both I and the market interpret as they want to gain TIME until the decision is made how they will finance the Phase II study, indicating that there is a higher probability today for a possible deal with Big Pharma regarding Foxy-5 this autumn ! The stock is significantly up today so far : finance.yahoo.com/quote/WNT.ST?p=WNT.STMy fundamental valuation IF a deal is reached is around SEK 600-1000 per share, that now costs around SEK 26, implying a "fairly acceptable" risk/reward ;-) www.infoom.se/mysite/index.php?sida=80579&user=9801
|
|
|
Post by loparn on Aug 21, 2017 11:22:52 GMT
|
|
|
Post by loparn on Aug 25, 2017 11:19:56 GMT
Surprisingly the CEO resigns. My best guess is that he could not deliver a good enough deal with Big Pharma according to the board and CSO who know the value of Foxy-5. www.aktietorget.se/NewsItem.aspx?ID=85184The stock is back where it was 1.5 week ago.
|
|
|
Post by loparn on Aug 30, 2017 20:46:55 GMT
|
|
|
Post by loparn on Aug 31, 2017 14:30:29 GMT
WntResearch has cancelled their presentation at Nordic Life Science Days Sept 14, and will only participate.
So an adequate number of Big Pharma now probably are already serious partner candidates :-)
No presentations to the stock market are planned, in spite of the weak balance sheet.
Many clues now point to a deal regarding Foxy-5 rather soon (I hope) !
|
|
|
Post by loparn on Sept 4, 2017 6:07:25 GMT
|
|
|
Post by loparn on Sept 5, 2017 10:05:47 GMT
A nightmare daytime : A new stock emission crashes the stock today. Excellent antimetastatic research, but sadly amateurs financially typical for biotech companies in Sweden. So now the stockholders may have to wait until the Phase II study is finished to receive their reward in a few years from now if succesful...
But new longterm stockholders are favored and can buy cheap.
|
|
|
Post by loparn on Sept 11, 2017 9:26:23 GMT
A new prostate cancer preclinical study is published with fine results for Foxy-5 in vitro and in mice. "WntResearch's Chief Scientific Officer, Professor Tommy Andersson, together with his research team, and in collaboration with Professor Anders Bjartell's research group, both at Lund University, has published a scientific article in the journal PLOS ONE. The article describes how Foxy-5 inhibits spread of prostate cancer cells in a model where Foxy-5 treatment is not commenced until after a primary tumor has been established in the prostate." www.aktietorget.se/NewsItem.aspx?ID=85468press.aktietorget.se/Wntresearch/85468/720570.pdf
|
|
|
Post by loparn on Sept 25, 2017 10:37:27 GMT
|
|
|
Post by loparn on Sept 11, 2018 13:38:36 GMT
The company has produced at lot of good news the last weeks and months. But the Phase II study is now scheduled to begin Q4 2018 but with a better design, as they begin giving Foxy-5 immediately after the diagnosis of colon cancer stage III. They now have no english spoken newseleases on the home page, but there is a new analysis by "Kapital Partners" which describes the current state of affairs, but their valuation of the stock is rather ignorant. gallery.mailchimp.com/b37c4695f194050744e659a1a/files/d3e39111-b4e6-4940-a5ac-ea06b58c8575/WntResearch_2018_09_03_2.pdf----------------- A new review deals with breast cancerstemcells, mentioning Foxy-5, see link below : ""Finally, two clinical trials have been started using Foxy-5, a formylated six amino acid peptide fragment that mimics the effects of Wnt5a, a non-canonical member of the Wnt family, which plays an important role in organ development, tissue orientation, cell polarity, and migration, thus, acting as an anti-metastatic cancer drug" But this summer it was announced that Foxy-5 really inhibits cancerstemcells. It has resulted in a new patent application. It is not surprising to me since different published studies taken toghether imply a possible anti cancestemcell-effect of Foxy-5 in breast and colon cancer. www.google.se/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=2ahUKEwjw_NqZl7PdAhURiaYKHYKVDrgQFjAGegQIABAC&url=http%3A%2F%2Fwww.mdpi.com%2F1420-3049%2F23%2F9%2F2193%2Fpdf&usg=AOvVaw0AC2aWNiIAQGZHFp9LTgFD
|
|
|
Post by loparn on Sept 12, 2018 8:52:29 GMT
Today WntResearch announced their application (Clinical Trial Authorization, CTA) for a Phase II study with Foxy-5 in colon cancer in Spain (and Netherlands). They will use ctDNA as a surrogate biomarker for effect, with interim results presented to the market, probably starting next year. Link in Swedish www.wntresearch.com/investor-media/news-releases.aspx?id=91124&category=eNewsItemThe preclinical mechanistic work regarding Foxy-5, 15-PGDH and patient survival is very very promising, see earlier post.
|
|
|
Post by loparn on Apr 11, 2019 10:50:01 GMT
A new preclinical study from the WntResearch CSO and his university research group regarding Foxy-5 and for example its reducing effect on cancerstemcells in mice has been published. Since the Phase II clinical study with Foxy-5 now is ongoing in colon cancer stage III (before metastases have developed) patients, this is of significant new value, since metastasis may be caused by cancerstemcells and/or epithelial cancercells after going through the EMT-process which Foxy-5 indirectly also has previously been shown to inhibit (according to studies on Wnt-5a in colon cancer and Foxy-5 can mimick Wnt-5a by signaling through their common receptor Frizzled-5). The study confirmed in vivo earlier in vitro results that Foxy-5 can significantly elevate the enzym 15-PGDH which is important in colon cancer since it reduces prostaglandin E2. A high expression of 15-PGDH in colon cancer patients priamary tumors is associated with a much longer median survival according to an earlier study by the CSO research group. ar.iiarjournals.org/content/39/4/1719.fullWntResearch estimates the potential sales of Foxy-5 in colon cancer to be around 2.3 billion USD, but also with similar sales potential in both breast and prostate cancer as well. Metastasis accounts for around 90 % of deaths i cancer and with minor adverse effects Foxy-5 should be possible to combine with other cancer therapies including chemotherapy and/or immune therapy. The WntResearch market capital now is still less than USD 25 million and the ongoing capital raize until next week should be sufficient to cover all the corporate costs to and including important interim data for possible antimetastatic effect via ctDNA data next year. If succefull data will occur next year (Q2 2020), the goal is stated to be exit according to the CEO two days ago in an official presentation in Stockholm, Sweden.
|
|
|
Post by loparn on May 14, 2019 7:08:30 GMT
|
|